TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a US$158 million Series B financing. The financing was led by Goldman Sachs Asset Management, with participation from UC, Office of the Chief Investment Officer, Bristol Myers Squibb, Deep Track Capital, Vertex Ventures HC, Moore Strategic Ventures, Cowen Healthcare Investments, Perceptive Xontogeny Venture Fund, and existing investors including Alexandria Venture Investments and OCV Partners.
Latham & Watkins LLP advises Goldman Sachs in the financing with a deal team led by Bay Area partner Saad Khanani, with Chicago associates Omar Ammash and Jay Trewn. Advise was also provided on tax matters by Bay Area partner Grace Lee and associate Alex Farris, and on benefits & compensation matters by Century City/Bay Area partner Julie Crisp.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
